Curated News
By: NewsRamp Editorial Staff
April 28, 2026

NeuroOne to Report Q2 FY2026 Results on May 12

Discuss on Substack Discuss on Telegram
Original Source

TLDR

  • NeuroOne (NMTC) reports Q2 FY2026 results May 12, offering investors early insight into its growing electrode market share.
  • NeuroOne will release Q2 earnings before market open May 12, followed by a conference call with management at 8:30 a.m. ET.
  • NeuroOne's electrode technology reduces hospitalizations and improves outcomes for patients with neurological disorders, advancing surgical care.
  • NeuroOne's FDA-cleared electrode platform enables both diagnostic and therapeutic functions, potentially reducing the need for multiple surgeries.

Impact - Why it Matters

This news matters because NeuroOne's financial results and corporate update will provide insights into the company's growth trajectory and the adoption of its innovative electrode technology platform, which has the potential to transform neurological surgeries. For patients and healthcare providers, advancements in NeuroOne's products could mean fewer procedures, reduced costs, and better outcomes for neurological disorders. Investors should monitor the earnings call for signs of market traction and future opportunities in areas like drug delivery and spinal cord stimulation.

Summary

NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) has announced that it will release its fiscal second quarter 2026 financial results before market open on May 12, 2026. The medical technology company, which focuses on transforming the surgical diagnosis and treatment of neurological disorders, will host an investor conference call and webcast at 8:30 a.m. Eastern time on the same day. The call will cover financial results, provide a corporate update, and feature a Q&A session with participants. Dial-in details include a toll-free U.S. number (888-506-0062) and an international number (973-528-0011), with participant access code 224785. A webcast is also available via the NMTC FY Q2 2026 Earnings Call Webcast link. The replay will be accessible through May 26, 2026, by phone (877-481-4010 in the U.S., 919-882-2331 internationally, passcode 53948) or via the webcast link until May 12, 2027.

NeuroOne markets a minimally invasive, high-definition/high-precision electrode technology platform with four FDA-cleared product families: Evo® Cortical Electrodes, Evo® sEEG Electrodes, OneRF® Ablation System (for brain), and OneRF® Trigeminal Nerve Ablation System. These solutions are designed to reduce hospitalizations and surgical procedures, lower costs, and improve patient outcomes by offering both diagnostic and therapeutic functions. The company is also engaged in research and development for drug delivery, basivertebral nerve ablation, and spinal cord stimulation programs. For more information, visit nmtc1.com.

This earnings release comes as NeuroOne continues to expand its footprint in the neurological medical device market. The company's focus on innovation and patient outcomes positions it as a key player in the industry. Investors and healthcare professionals alike will be watching closely for updates on the company's financial performance and strategic direction, particularly regarding its R&D pipeline and potential new product approvals.

Source Statement

This curated news summary relied on content disributed by NewMediaWire. Read the original source here, NeuroOne to Report Q2 FY2026 Results on May 12

blockchain registration record for this content.